The relationship of serum asymmetric dimethylarginine concentrations and lung involvement in patients with COVID-19 infection

Keywords: COVID-19, pneumonia, endothelial dysfunction, asymmetric dimethylarginine, CRP

Abstract

Aim: COVID-19 infections the tissue through angiotensin converting enzyme 2 receptor, which is also expressed on endothelial cells. Endothelial dysfunction may be associated with lung involvement. Asymmetric dimethylarginine (ADMA) is an indirect marker of endothelial dysfunction. The aim of our study was to evaluate ADMA concentrations and to identify its association with lung involvement in patients with COVID-19 disease.

Methods: We included 42 patients with COVID-19 infection and lung involvement (Group 1). Forty-two age and sex matched patients without pneumonia acted as the control group (Group 2). All patients gave blood samples for ADMA at the 1st month control visit after discharge. We compared C-reactive protein (CRP) and ADMA concentrations in addition to routine biochemical parameters between groups.

Results: Patients with lung involvement had higher admission glucose, CRP, and ADMA concentrations, and displayed lower hemoglobin concentration and lymphocyte count compared to patients without lung involvement. Although patients with lung involvement had higher ADMA concentrations with respect to those without; plasma ADMA levels were also higher than normal values in control group. Multivariate analysis identified log CRP concentration (OR= 3.047, 95% CI=1.881-5.023, p<0.001) as the independent predictor for lung involvement. And, there was a correlation between ADMA and CRP (r: 0.318, p: 0.003).

Conclusion: We revealed elevated ADMA concentrations as the surrogate of endothelial dysfunction in COVID-19 patients whether they have pneumonia or not.

Published
2021-09-21
How to Cite
Emlek, N., Yilmaz, A., Ergul, E., Gundogdu, H., Arpa, M., Koc, H., Ozturk, M., & Aydin, C. (2021, September 21). The relationship of serum asymmetric dimethylarginine concentrations and lung involvement in patients with COVID-19 infection. EXPERIMENTAL BIOMEDICAL RESEARCH, 4(4), 314-321. https://doi.org/https://doi.org/10.30714/j-ebr.2021471926